


Amendments to the claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A compound of formula (I), a pharmaceutically acceptable salt, solvate or derivative thereof:



wherein

X is N or CH;

R¹ is selected from hydrogen, C₁₋₆alkyl, C₁₋₆alkenyl, C₁₋₆alkoxy, halo, cyano, perfluoro C₁₋₆alkyl, perfluoroC₁₋₆alkoxy, -NR⁵R⁶, -(CH₂)_nNR⁵R⁶, -O(CH₂)_nOR⁷, -O(CH₂)_n-Het, -O(CH₂)_nNR⁵R⁶, -CONR⁵R⁶, -C(O)R⁷, -CO(CH₂)_nNR⁵R⁶, -SO₂R⁷, -SO₂NR⁵R⁶, -NR⁵SO₂R⁷, -NR⁵COR⁷ and -O(CH₂)_nCONR⁵R⁶;

R² is hydrogen, C₁₋₆alkyl, halo, cyano or perfluoroC₁₋₆alkyl;

R³ is hydrogen or halo;

R⁴ is hydrogen, halo, C₁₋₆alkyl or -NR⁵R⁶;

R⁵ and R⁶ are independently selected from hydrogen, C₁₋₆alkyl, perfluoroC₁₋₆alkyl, Het or C₁₋₄alkoxyC₁₋₄alkyl; or R⁵ and R⁶ together with the nitrogen atom to which they are attached form a 3, 4, 5, 6 or 7-membered saturated or unsaturated ring which may contain one or more heteroatoms selected from N, S or O, and wherein the ring may be further substituted by one or more substituents selected from halo

(such as fluoro, chloro, bromo), cyano, $-\text{CF}_3$, hydroxy, $-\text{OCF}_3$, C_{1-6} alkyl and C_{1-6} alkoxy;

R^7 is hydrogen or C_{1-6} alkyl;

Het is a 5 or 6-membered C-linked heterocyclyl group which may be saturated, unsaturated or aromatic, which may contain one or more heteroatoms selected from N, S or O and which may be substituted by C_{1-6} alkyl; and

n is 1-4.

2. (Original) A compound according to claim 1 wherein X is N.
3. (Currently Amended) A compound according to ~~any preceding claim~~ claim 1 wherein R^1 is $-\text{NR}^5\text{R}^6$, $-(\text{CH}_2)_n\text{NR}^5\text{R}^6$, $-\text{O}(\text{CH}_2)_n\text{NR}^5\text{R}^6$, $-\text{O}(\text{CH}_2)_n\text{-Het}$, $-\text{CONR}^5\text{R}^6$, $-\text{CO}(\text{CH}_2)_n\text{NR}^5\text{R}^6$ or $-\text{SO}_2\text{R}^7$.
4. (Currently Amended) A compound according to ~~any preceding claim~~ claim 1 wherein R^2 is hydrogen, C_{1-6} alkyl, chloro or fluoro.
5. (Currently Amended) A compound according to ~~any preceding claim~~ claim 1 wherein R^3 is hydrogen or fluoro.
6. (Currently Amended) A compound according to ~~any preceding claim~~ claim 1 wherein when X is N, R^2 is methyl.
7. (Currently Amended) A compound according to ~~any preceding claim~~ claim 1 wherein when X is N and R^2 is methyl, R^3 is hydrogen.
8. (Currently Amended) A compound according to ~~any preceding claim~~ claim 1 wherein R^4 is hydrogen, C_{1-6} alkyl or halo.

9. (Currently Amended) A compound according to ~~any preceding claim~~ claim 1 wherein R^5 and R^6 are independently hydrogen, methyl or Het; or R^5 and R^6 together with the nitrogen atom to which they are attached form a 3, 4, 5, 6 or 7 membered saturated or unsaturated ring which may contain one or more heteroatoms selected from N, S or O, and wherein the ring may be further substituted by one or more substituents selected from halo (such as fluoro, chloro, bromo), cyano, $-CF_3$, hydroxy, $-OCF_3$, C_{1-4} alkyl and C_{1-4} alkoxy.

10. (Currently Amended) A compound according to ~~any preceding claim~~ claim 1 wherein R^5 and R^6 are independently hydrogen, methyl or tetrahydropyranyl; or R^5 and R^6 together with the nitrogen atom to which they are attached form a morpholine, pyrrolidine, piperazine ring, each of which may be substituted by halo (such as fluoro, chloro, bromo), cyano, $-CF_3$, hydroxy, $-OCF_3$, C_{1-4} alkyl or C_{1-4} alkoxy.

11. (Original) A compound according to claim 1 wherein
X is N;

R^1 is $-NR^5R^6$, $-(CH_2)_nNR^5R^6$, $-O(CH_2)_nNR^5R^6$, $-O(CH_2)_n$ -Het, $-CONR^5R^6$,
 $-CO(CH_2)_nNR^5R^6$ or $-SO_2R^7$;

R^2 is hydrogen, C_{1-6} alkyl, chloro or fluoro;

R^3 is hydrogen or fluoro;

R^4 is hydrogen, C_{1-6} alkyl or halo;

R^5 and R^6 are independently hydrogen, methyl or Het; or R^5 and R^6 together with the nitrogen atom to which they are attached form a 3, 4, 5, 6 or 7 membered saturated or unsaturated ring which may contain one or more heteroatoms selected from N, S or O, and wherein the ring may be further substituted by one or more substituents selected from halo (such as fluoro, chloro, bromo), cyano, $-CF_3$, hydroxy, $-OCF_3$, C_{1-4} alkyl and C_{1-4} alkoxy;

R^7 is hydrogen or C_{1-6} alkyl;

Het is a 5 or 6-membered C-linked heterocyclyl group which may be saturated, unsaturated or aromatic, which may contain one or more

heteroatoms selected from N, S or O and which may be substituted by
C₁₋₆alkyl; and

n is 1-4.

12. (Original) A compound according to claim 1 selected from the list:

3-[2-(4-methanesulfonyl-phenyl)-pyridin-4-yl]-2-(6-methyl-pyridin-2-yl)-
imidazo[1,2-a]pyridine (Example 6);

3-[2-(4-(morpholin-4-yl)-phenyl)-pyridin-4-yl]-2-pyridin-2-yl-imidazo[1,2-
a]pyridine (Example 14);

3-{2-[4-(4-methylpiperazin-1-yl)-phenyl]-pyridin-4-yl}-2-pyridin-2-yl-
imidazo[1,2-a]pyridine (Example 15);

2-(6-methyl-pyridin-2-yl)-3-[2-(4-(morpholin-4-ylmethyl)phenyl)-pyridin-4-
yl]-imidazo[1,2-a]pyridine (Example 16);

2-(6-methyl-pyridin-2-yl)-3-{2-[4-((morpholin-4-yl)carbonyl)phenyl]-pyridin-
4-yl}-imidazo[1,2-a]pyridine (Example 29);

2-(pyridin-2-yl)-3-{2-[4-(2-(pyrrolidin-1-yl)ethoxy)phenyl]-pyridin-4-yl}-
imidazo[1,2-a]pyridine (Example 34);

7-methyl-2-(6-methyl-pyridin-2-yl)-3-{2-[4-(2-(pyrrolidin-1-
yl)ethoxy)phenyl]-pyridin-4-yl}-imidazo[1,2-a]pyridine (Example 38);

7-methyl-2-(6-methyl-pyridin-2-yl)-3-{2-[4-((1-methyl-imidazol-4-
yl)methyloxy)phenyl]-pyridin-4-yl}-imidazo[1,2-a]pyridine (Example
41); and

7-methyl-2-(6-methyl-pyridin-2-yl)-3-{2-
[4(aminocarbonylmethyloxy)phenyl]-pyridin-4-yl}-imidazo[1,2-
a]pyridine (Example 43);

and pharmaceutically acceptable salts, solvates and derivatives thereof.

13. (Currently Amended) A pharmaceutical composition comprising a
compound defined in ~~any preceding claim~~ claim 1 and a pharmaceutically
acceptable carrier or diluent.

14 – 17 (Cancelled).

18. (New) A method of treatment or prophylaxis of a disorder mediated by the ALK5 receptor in mammals, wherein the disorder is selected from chronic renal disease, acute renal disease, wound healing, arthritis, osteoporosis, kidney disease, congestive heart failure, ulcers, ocular disorders, corneal wounds, diabetic nephropathy, impaired neurological function, Alzheimer's disease, atherosclerosis, peritoneal and sub-dermal adhesion, any disease wherein fibrosis is a major component, including, but not limited to lung fibrosis, kidney fibrosis, liver fibrosis [for example, hepatitis B virus (HBV), hepatitis C virus (HCV)], alcohol induced hepatitis, retroperitoneal fibrosis, mesenteric fibrosis, haemochromatosis and primary biliary cirrhosis, endometriosis, keloids and restenosis comprising administering to a mammal in need thereof a compound according to claim 1.